Compare ADMA Biologics Inc (ADMA) vs Blackstone Inc (BX) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

BX trades at $120.88, down 1.51% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $12.41B in 2025, with a net income margin of 24.27% and robust ROE of 37.36%. Recent news highlights strategic moves in energy transition, AI data centers, and credit markets, including a $30B Japan AI investment plan reported by Reuters on June 23, 2026.

Outlook remains positive with a consensus price target of $150.78, implying 25% upside, supported by 62% analyst buy ratings. Risks include execution of large investments and market volatility, but fundamentals and institutional sentiment favor long-term growth.